Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
But it's usually lonely in "undiscovered stocks" rooms.
I don't care. Long as they are going up I'm happy.
Arkin and Geiger founded AccelMed during the economic crisis in order to exploit opportunities it created to invest in medical devices companies. The fund has several tens of millions of dollars under management. It has invested in Exalenz Bioscience Ltd. (TASE:EXEN), MCS Medical Compression Systems (DBN) Ltd. (TASE:MDCL), Edge Medical Devices Ltd. , and Ophthalmic Imaging Systems Inc. (Bulletin Board: OISI).
Spine implant co NLT raises $8.8m: The start-up's investors include new Teva chairman Philip Frost. [Globes, Tel Aviv, Israel] Knight Ridder/Tribune "Business News "
Mar. 18 --Minimally invasive surgery spinal implant developer Non Linear Technologies Ltd. (NLT) has raised $8.8 million . Moshe (Mori) Arkin and Dr. Uri Geiger's Accelmed led the round, alongside current investor Peregrine Ventures , which has funded the company since it was at the fund's Incentive Technological Incubator. Peregrine partner and Teva chairman Philip Frost also invested his own funds. The company has raised $10 million to date, including the present round.
Geiger will become chairman of NLT.
NLT was founded by spinal surgeon Dr. Tzony Siegal, who developed the method for inserting spinal implants in a minimally invasive way. The implants are inserted bit by bit through a thin pipe, wire, or carry wire.
Each part of the implant is inserted in a compressed form, and open when in place in the body. When all the components are inserted, the wire is pulled. Pulling on the wire connects the sections, and the implant acquires its final desired shape.
NLT CEO Didier Toubia says that the technology platform can be used for almost all types of current spinal treatments and implants. The spinal treatment and implants market amounts to $5 billion .
NLT has two main products: vertebrae fusion products (which represent 80 percent of the US spinal implants market), which is in preclinical testing, and products for strengthening the spine's stability while retaining its flexibility, which is in clinical trials.
Toubia believes that the present financing will be enough to obtain certification of the vertebrae fusion product and complete the clinical trial for the products that allow patients more movement. "At this stage, we have enough assets to begin penetrating the market. In the US, we'll seek a partner, and in Europe , we sell on our own through distributors," he said.
Arkin and Geiger founded AccelMed during the economic crisis in order to exploit opportunities it created to invest in medical devices companies. The fund has several tens of millions of dollars under management. It has invested in Exalenz Bioscience Ltd. (TASE:EXEN), MCS Medical Compression Systems (DBN) Ltd. (TASE:MDCL), Edge Medical Devices Ltd. , and Ophthalmic Imaging Systems Inc. (Bulletin Board: OISI).
Geiger told "Globes", "Although the crisis is more or less over, and valuations for investment in medical devices companies has risen, we'll continue to invest in companies until we have 6-8 companies in our portfolio, the target we set when we set up the fund.
As for NLT, Geiger said, "We like that the company is developing a solution for minimally invasive spinal surgery that barely changes the surgeon's work method."
To see more of the Globes or to subscribe to the newspaper, go to http://www.globes-online.com.
Copyright (c) 2010, Globes, Tel Aviv, Israel
Distributed by McClatchy-Tribune Information Services. For reprints, email tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc. , 1247 Milwaukee Ave. , Suite 303, Glenview, IL 60025, USA .
About time. That's all I can say.
I love "off rader" stocks sometimes. Especially ones like this.
Good luck Brick.
I'm resigning as mod. It has nothing to do with whether I'm holding or not. To prevent any confusion when I resign suddenly on one stock specific board, I'm resigning from all stock specific boards. Good luck to all of us.
Trend should resume next week I think.
Yes. Still too much pain making an exit from getting caught in last run up.
Will take time.
Yes but that is not unusual from what I see in OISI past price history.
Even with the last positive development OISI is practically an unknown company/stock.
Not that I like that fact but at least it gives me more confidence that PPS will continue to appriciate in it's trend.
Have you checked out the chart for 2009? WoW!
Looks like only a matter of time before OISI breaks the 200MA and goes on to make new highs.
Looks like key resistance at $1.25 around 200MA
I would also say that new PR's are coming about sales from new device.
Thoughts?
Shame really, this is a nice company and stock
I guess we have some people cutting losses and getting out from the run up. Not willing to wait.
OISI Ophthalmic Imaging Systems DD:
Ophthalmic Imaging Systems (www.oisi.com) is the leading provider of ophthalmic digital imaging systems. The Company designs, develops, manufactures and markets digital imaging systems, image management and integrated EMR/Practice Management solutions for the eye care market. With over twenty years in the ophthalmic imaging business, the Company has consistently introduced new, innovative technologies. Through OIS' wholly-owned subsidiary, Abraxas Medical Solutions, the company provides Electronic Medical Records and Practice Management software to Ophthalmology as well as OB/GYN, Orthopedic and Primary care. The Company markets and supports its products through an extensive network of dealers, distributors, and direct representatives.
************************************************************************
Share Structure as of Sept 30, 2009:
Authorized Shares: 35,000,000
Outstanding Shares: 26,500,059
Float: 16,761,831
Outstanding Shares as of November 30, 2009: 26,500,059
Major Holders Breakdown:
% of Shares Held by All Insider and 5% Owners: 36%
% of Shares Held by Institutional & Mutual Fund Owners: 5%
% of Float Held by Institutional & Mutual Fund Owners: 8%
Number of Institutions Holding Shares: 3
Insider Holders:
Holder/Shares/Reported
U.M. Accelmed, Ltd Partnership 9,633,228 June 24, 2009
Allon Gil 60,000 December 3, 2008
Shenhar Ariel 30,000 December 10, 2008
Phillips Jonathan R 15,000 May 23, 2008
Institutional Holders:
Holder/Shares.Reported
Perritt Capital Management, Inc. 710,000 September 30, 2009
Bard Associates Inc. 544,400 September 30, 2009
Blair (William) & Company, L. L. C. 15,500 September 30, 2009
Mutual Fund Holder:
Holder/Shares/Reported
Perritt Emerging Opportunities Fund 665,000 September 30, 2009
Investor Relations:
KCSA Strategic Communications
Todd Fromer 212-896-1215
Garth Russell 212-896-1250
************************************************************************
Contacts:
Gil Allon, CEO
(916) 646-2020
Ariel Shenhar, CFO
ashenhar@oisi.com
P: 800.338.8436
F: 916.646.0207
Ophthalmic Imaging Systems Inc
221 Lathrop Way
Suite I
Sacramento, CA 95815
P: +1916.6462020
F: +1916.6460207
************************************************************************
Financials from 10Q as of September 30, 2009:
Cash and cash equivalents $4,811,027
Total current assets 8,564,468
Total assets $10,886,902
Total current liabilities 3,960,308
Total liabilities 5,478,591
Sales, Three months ended September 30, $2,765,878
Net income (loss) $ 85,656
Net increase (decrease) in cash and equivalents 2,586,402
Cash and equivalents, beginning of the period 2,224,625
Cash and equivalents, end of the period $ 4,811,027
************************************************************************
Ophthalmic Imaging Systems Receives FDA Clearance to Market Revolutionary New Portable Digital Imaging Device http://investorshub.advfn.com/boards/read_msg.aspx?message_id=44032138
All News: http://ih.advfn.com/p.php?pid=news&cb=1259633917&symbol=OISI
All SEC Filings: http://www.sec.gov/cgi-bin/browse-edgar?company=Ophthalmic+Imaging&match=&CIK=&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany
IHub Message Board: http://investorshub.advfn.com/boards/board.aspx?board_id=13727
Charts by MrGreenPenny: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=44039890
************************************************************************
Officers and Directors:
Name Age Since Current Position
Phillips, Jonathan 36 2007 Independent Director
Greer, William 42 2007 Independent Director
Maurincomme, Eric 42 2008 Independent Director
Inbar, Menachem 60 2009 Independent Director
Geiger, Uri 41 2009 Director
Shenhar, Ariel 43 2002 Chief Financial Officer, Vice President, Secretary, Director
Allon, Gil 47 2002 Chief Executive Officer, Director
Ram, Uri 60 2009 Chairman of the Board
Mr. Gil Allon is Chief Executive Officer, Director of Ophthalmic Imaging Systems. He is Board of Directors since August 2000 and has served as Chief Executive Officer since January 2002. Mr. Allon has acted in the capacity of Chief Executive Officer since August 2000. Mr. Allon is also a member of the Compensation, Option and Nominations Committees of Board of Directors. Mr. Allon served as the Vice President and chief Operating Officer of MediVision from June 1993 until August 2000. Mr. Allon also served as a member of the Board of Directors of MediVision since MediVision’s inception in June 1993 through December 2004. Mr. Allon received his B.A. and M.Sc. in Computer Science, both with distinction, from the Technion Israel Institute of Technology in Haifa, Israel in May 1987 and December 1989, respectively, and his M.B.A. with distinction in Business Management from the University of Haifa in September 1999.
Mr. Uri Ram is Chairman of the Board of Ophthalmic Imaging Systems since March 2009. He was recommended for the director position by Yigal Berman, a former director of board. He was appointed as an independent director and Chairman of Board in March 2009. Mr. Ram is the Chairman of the Audit Committee and a member of the Compensation, Option and Nominations Committees of Board. Currently, he serves as the Sr. Vice President and Chief Financial Officer of Gefen Inc. and is the CEO/Owner of Juram Ltd. and Irams Inc., management consulting companies that also invests in new startups. Since 1990, Mr. Ram has served as the President of Del-Ta Engineering & Equipment Ltd., a holding company with $30 million in sales and as the Senior VP of Inter-Gamma Investment Ltd. Inter-Gamma Investment Ltd. is a shareholder of MediVision Medical Imaging Ltd., parent company. Mr. Ram has a Master of Arts degree from Israel National Defense College, and a Bachelor of Economics and Political sciences from Bar Ilan University and participated in an EMBA program at the Tel Aviv University. Mr. Ram is a retired Brigadier General of the Israeli Air Force.
Mr. Ariel Shenhar is Chief Financial Officer, Vice President, Secretary, Director of Ophthalmic Imaging Systems. He is Directors since August 2000, has served as Vice President and Chief Financial Officer since July 2002 and has served as Secretary since August 2002. Mr. Shenhar also served as a member of the Board of Directors of MediVision from August 1994 through December 2004 and as its Vice President and Chief Financial Officer from January 1997 until May 2005. Mr. Shenhar served as a member of the Board of Directors of Fidelity Gold Real Estate Markets Ltd., an Israeli public company engaged in real estate, from 1994 to 1998, as an accountant at Nissan Caspi & Co. Certified Public Accountants in Jerusalem, Israel in 1996, and at Witkowski & Co. Certified Public Accountants in Tel Aviv, Israel from 1994 to 1995. Mr. Shenhar received his B.A. in Economics and Accounting in June 1992 and his M.B.A. in Finance, with distinction, in June 1999 both from the Hebrew University in Jerusalem, Israel, and has been a Certified Public Accountant since January 1997.
************************************************************************
Recent Developments:
Ophthalmic Imaging Systems (OIS) Receives FDA Clearance To Market Revolutionary New Portable Digital Imaging Device, Monday 30 Oct 09
Ophthalmic Imaging Systems (OIS) announced that its revolutionary new portable imaging device, the OIS EyeScan, has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA).
Ophthalmic Imaging Systems (OIS) to Launch OIS EyeScan and Other New Products at American Academy of Ophthalmology's, Thursday, 22 Oct 2009
Ophthalmic Imaging Systems (OIS) announced that it will launch two new products and improvements to the OIS EMR and OIS PM solutions at the American Academy of Ophthalmology's (AAO) 113th Annual Meeting, being held October 24 - 27, 2009, at the Moscone Convention Center in San Francisco, CA. The new products are: OIS EyeScan-The OIS EyeScan is a revolutionary new portable imaging device that is capable of imaging both the anterior and posterior segment of the eye and OIS Symphony Digital Reporter
Ophthalmic Imaging Systems (OIS) Announces Private Equity Financing, Monday, 29 Jun 2009
Ophthalmic Imaging Systems (OIS) announced it has signed a purchase agreement with U.M. AccelMed (AccelMed), Limited Partnership for a $6.0 million private placement of the Company`s common stock and warrants to be completed in two installments. Under the terms of the purchase agreement, OIS may issue up to an aggregate of 13,214,317 shares of its common stock and warrants to purchase up to an aggregate of 4,404,772 shares of its common stock. The Company intends to use the net proceeds for working capital and general corporate purposes. The first installment of $4.0 million was completed on June 24, 2009. In the first installment OIS sold 9,633,228 shares of common stock at a purchase price of $0.415 per share and issued three-year warrants to purchase up to 3,211,076 shares of common stock at $1.00 per share. The second installment of $2.0 million, consisting of 3,581,089 shares of common stock at a purchase price of $0.558 per share and warrants to purchase 1,193,696 shares of common stock at $1.00 per share, is expected to be completed by April 15, 2010.
Ophthalmic Imaging Systems (OIS) Announces Resignation Of Mr. Berman As Chairman-Form 8-K, Thursday, 19 Mar 2009
Ophthalmic Imaging Systems (OIS) announced in its Form 8-K that Yigal Berman has notified the Company of his resignation from the Company's Board of Directors (the Board) as a result of health issues, effective immediately. As of such date, Mr. Berman was the Chairman of the Board and Chairman of its Audit, Compensation, Option, and Nominations Committees of the Board. On March 18, 2009, the Board has appointed Mr. Ram as its Chairman as well as Chairman of the Audit Committee and as a member of the Compensation, Option and Nominations Committees.
Ophthalmic Imaging Systems (OIS) To Launch Seven New Products, Wednesday, 5 Nov 2008
Ophthalmic Imaging Systems (OIS) announced that it will launch seven new software solutions. The seven new products to be introduced will include OIS EMR, OIS PM, Symphony WebTM, Symphony Draw, Symphony Link, PerfectView and FAF Super-Resolution.
This post is in my opinion.
Need better volume than this. I am holding all of mine.
Looks like some people who bought too high on the spike yesterday are selling. I bought more today in the .80's .81 to be specific.
Usually this is not a good idea but with this company and tech I can't see it going anywhere but up from here. Just look at the chart and the filings.
With the new device they will now make more money in the coming quarters than ever.
I may buy even more if another seller gets impatient.
This is a rare stock. It's a dream come true Really, Wow. For more reasons than one.
Penny land never ceases to amaze me.
I have searched day after day for uptrending stocks like OISI and a jewel like this slips by me! Errrrrrrr. Actually that kinda makes me mad. I should have found this one earlier due to the Up Trend.
I mean just look at the charts!,..I would have bought this one because of the uptrennd Much Much Much earlier if I had known about it!
Daily
Weekly
I'm not saying that it will run as much as VRMLQ but quite honestly it is like a little brother to VRMLQ. In other words with this FDA clearance to market the new revolutionary eye product I think it will help this little company go from just a "player" to a "contender" in it's given market.
Do a little digging and you will see why.
And the float! Perfect! Not too much....not to little.
Have you looked at the last few Q's? They were doing great even before this development!
Technically speaking we are headed to breakthrough all past resistance points.
Incase you can't tell I'm excited to be here.
I look forward to the weeks/months that come.
Major Holders BREAKDOWN
% of Shares Held by All Insider and 5% Owners: 36%
% of Shares Held by Institutional & Mutual Fund Owners: 5%
% of Float Held by Institutional & Mutual Fund Owners: 8%
Number of Institutions Holding Shares: 3
TOP MUTUAL FUND HOLDERS
Holder Shares % Out Value* Reported
PERRITT EMERGING OPPORTUNITIES FUND 665,000 2.51 $365,750 30-Sep-09
TOP INSTITUTIONAL HOLDERS
Holder Shares % Out Value* Reported
PERRITT CAPITAL MANAGEMENT, INC. 710,000 2.68 $390,500 30-Sep-09
Bard Associates Inc. 544,400 2.05 $299,420 30-Sep-09
BLAIR (WILLIAM) & COMPANY, L.L.C. 15,500 .06 $8,525 30-Sep-09
MAJOR DIRECT HOLDERS (FORMS 3 & 4)
Holder Shares Reported
U.M. ACCELMED, LIMITED PARTNERSHIP 9,633,228 24-Jun-09
ALLON GIL 60,000 3-Dec-08
SHENHAR ARIEL 30,000 10-Dec-08
PHILLIPS JONATHAN R 15,000 23-May-08
INVESTOR RELATIONS (OISI)
KCSA Strategic Communications
Todd Fromer
212-896-1215
Garth Russell
212-896-1250
About Ophthalmic Imaging Systems - OISI
Ophthalmic Imaging Systems (www.oisi.com) is the leading provider of ophthalmic digital imaging systems. The Company designs, develops, manufactures and markets digital imaging systems, image management and integrated EMR/Practice Management solutions for the eye care market. With over twenty years in the ophthalmic imaging business, the Company has consistently introduced new, innovative technologies. Through OIS' wholly-owned subsidiary, Abraxas Medical Solutions, the company provides Electronic Medical Records and Practice Management software to Ophthalmology as well as OB/GYN, Orthopedic and Primary care. The Company markets and supports its products through an extensive network of dealers, distributors, and direct representatives.
OISI S/S as of Sept 30, 2009:
Authorized Shares: 35,000,000
Outstanding Shares: 26,500,059
Float: 16,761,831
6/24/2009 U.M. AccelMed, Limited Partnership - Initial Statement of Beneficial Ownership (3)
Common stock 9633228
On June 24, 2009, Ophthalmic Imaging Systems (the "Company") entered into a Purchase Agreement (the "Purchase Agreement") with U.M. AccelMed, Limited Partnership ("AccelMed"), pursuant to which the Company agreed to issue and sell to AccelMed up to an aggregate of 13,214,317 shares of the Company's common stock, no par value (the "Common Stock"), and warrants to purchase up to an aggregate of 4,404,772 shares of Common Stock in two installments.
For the first installment, completed on June 24, 2009, the Company issued to AccelMed 9,633,228 shares of Common Stock and a warrant to purchase up to 3,211,076 shares of Common Stock, for an aggregate purchase price of $3,999,909. For the second installment (the "2nd Installment"), the Company will issue to AccelMed 3,581,089 shares of Common Stock and a warrant to purchase up to 1,193,696 shares of Common Stock, for an aggregate purchase price of $1,999,967. Subject to certain conditions set forth in the Purchase Agreement, which includes, without limitation, the achievement of certain financial milestones, the completion of the 2nd Installment will occur within 14 days of the date of the Company's filing of its Form 10-Q for the quarter ended March 31, 2010 or on a later date as may be agreed to in writing by the parties.
These securities are owned directly by AccelMed and indirectly by A.M. AccelMed Management (2009) Ltd., the general partner of AccelMed (the "General Partner"), M. Arkin (1999) Ltd ("M. Arkin (1999)"), the beneficial owner of 80% of the outstanding shares of the General Partner, and Moshe Arkin, the sole director and the beneficial owner of 99.9% of the outstanding shares of M. Arkin (1999) and a director of the Company.
The filing of this Form 3 shall not be construed as an admission that the General Partner, M. Arkin (1999) or Mr. Arkin is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, the beneficial owner of any of the shares of Common Stock of the Company owned by AccelMed. Pursuant to Rule 16a-1, each of the General Partner, M. Arkin (1999) and Mr. Arkin disclaim beneficial ownership of the shares of the Company reported herein that are beneficially owned by AccelMed, except to the extent of their pecuniary interest therein.
11/02/2009 RAM URI Statement of Changes in Beneficial Ownership (4)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 30000
Vesting in 6 installments, to purchase 5,000 shares of common stock in each installment, on the following dates: October 29, 2009, March 13, 2010, September 13, 2010, March 13, 2011, September 13, 2011 and March 13, 2012.
For the three months ended September 30, 2009, OIS reported a net revenue increase of 24% to $3.9 million compared to $3.2 million for the same period in 2008. The increase in revenue is due to an increase in product sales of approximately $668,000 and an increase in service revenue of approximately $91,000. Net income for the quarter ended September 30, 2009 was $86,000, or $0.00 per basic and diluted share, compared with a net loss for the quarter ended September 30, 2008 of $(416,000), or $(0.02) per basic and diluted share.
this should go green next couple of days. 9olume quite low today.
I got in today, lets see where this heads tomorrow. I hope we take down $1.30 soon, as of now it is blue sky breakout beyond that
- Crowded Mind
lol, there's a couple of peeps you can introduce yourself to now, if you aren't shy.
I would think we would have a huge gapper in the morning.
I gotta run darn it. I bet this place is packed when I get back tonight!
I agree Brick. This is one that I can hold and sleep tonight.
Historical Prices
Date Open High Low Close Volume Adj
Close
2009/11/27 0.64 0.64 0.64 0.64 100 0.64
2009/11/26 0.64 0.64 0.64 0.64 100 0.64
2009/11/25 0.64 0.64 0.64 0.64 100 0.64
2009/11/24 0.67 0.67 0.60 0.60 17,200 0.60
2009/11/23 0.68 0.68 0.62 0.65 45,000 0.65
2009/11/20 0.65 0.65 0.65 0.65 100 0.65
2009/11/19 0.65 0.65 0.51 0.65 16,900 0.65
2009/11/18 0.65 0.65 0.65 0.65 1,500 0.65
2009/11/17 0.70 0.70 0.62 0.65 25,750 0.65
2009/11/16 0.65 0.65 0.65 0.65 15,450 0.65
2009/11/13 0.63 0.65 0.63 0.65 3,260 0.65
2009/11/12 0.60 0.65 0.60 0.65 13,212 0.65
2009/11/11 0.60 0.60 0.60 0.60 5,000 0.60
2009/11/10 0.56 0.56 0.56 0.56 3,500 0.56
2009/11/09 0.59 0.60 0.58 0.60 12,200 0.60
2009/11/06 0.59 0.59 0.59 0.59 - 0.59
2009/11/05 0.59 0.59 0.59 0.59 - 0.59
2009/11/04 0.56 0.59 0.56 0.59 31,299 0.59
2009/11/03 0.59 0.59 0.59 0.59 1,500 0.59
2009/11/02 0.59 0.59 0.59 0.59 14,000 0.59
2009/10/30 0.57 0.59 0.55 0.59 7,500 0.59
2009/10/29 0.55 0.60 0.55 0.60 46,800 0.60
2009/10/28 0.55 0.55 0.55 0.55 - 0.55
2009/10/27 0.55 0.56 0.55 0.55 59,040 0.55
2009/10/26 0.55 0.55 0.55 0.55 - 0.55
2009/10/23 0.54 0.55 0.45 0.55 7,900 0.55
2009/10/22 0.54 0.54 0.54 0.54 100 0.54
2009/10/21 0.54 0.54 0.54 0.54 - 0.54
2009/10/20 0.48 0.54 0.48 0.54 3,600 0.54
2009/10/19 0.50 0.50 0.48 0.48 23,000 0.48
2009/10/16 0.50 0.50 0.50 0.50 27,000 0.50
2009/10/15 0.50 0.50 0.50 0.50 - 0.50
2009/10/14 0.48 0.50 0.48 0.50 8,300 0.50
2009/10/13 0.54 0.54 0.50 0.50 36,100 0.50
2009/10/12 0.54 0.54 0.54 0.54 - 0.54
2009/10/09 0.54 0.54 0.54 0.54 - 0.54
2009/10/08 0.54 0.54 0.54 0.54 100 0.54
2009/10/07 0.54 0.54 0.54 0.54 - 0.54
2009/10/06 0.50 0.54 0.45 0.54 2,866 0.54
2009/10/05 0.55 0.55 0.55 0.55 - 0.55
2009/10/02 0.55 0.55 0.55 0.55 - 0.55
2009/10/01 0.55 0.55 0.55 0.55 500 0.55
2009/09/30 0.55 0.55 0.55 0.55 - 0.55
2009/09/29 0.55 0.55 0.55 0.55 7,600 0.55
2009/09/28 0.55 0.55 0.55 0.55 - 0.55
2009/09/25 0.54 0.55 0.54 0.55 11,000 0.55
2009/09/24 0.53 0.55 0.45 0.55 11,565 0.55
2009/09/23 0.51 0.54 0.51 0.53 43,084 0.53
2009/09/22 0.50 0.53 0.50 0.53 9,000 0.53
2009/09/21 0.50 0.50 0.45 0.50 24,500 0.50
2009/09/18 0.45 0.51 0.45 0.51 2,800 0.51
2009/09/17 0.53 0.53 0.26 0.41 102,721 0.41
2009/09/16 0.53 0.53 0.53 0.53 13,000 0.53
2009/09/15 0.51 0.51 0.51 0.51 - 0.51
2009/09/14 0.51 0.51 0.51 0.51 10,200 0.51
2009/09/11 0.50 0.50 0.50 0.50 11,000 0.50
2009/09/10 0.55 0.55 0.55 0.55 - 0.55
2009/09/09 0.55 0.55 0.55 0.55 100 0.55
2009/09/08 0.45 0.55 0.45 0.55 4,100 0.55
2009/09/07 0.45 0.55 0.45 0.55 350 0.55
2009/09/04 0.45 0.55 0.45 0.55 350 0.55
2009/09/03 0.55 0.55 0.55 0.55 3,200 0.55
2009/09/02 0.55 0.59 0.55 0.55 24,350 0.55
2009/09/01 0.53 0.54 0.53 0.53 36,500 0.53
2009/08/31 0.50 0.51 0.50 0.51 22,100 0.51
2009/08/28 0.50 0.50 0.50 0.50 5,500 0.50
2009/08/27 0.48 0.48 0.48 0.48 5,051 0.48
2009/08/26 0.47 0.47 0.47 0.47 5,500 0.47
2009/08/25 0.45 0.45 0.45 0.45 - 0.45
2009/08/24 0.45 0.45 0.45 0.45 6,000 0.45
2009/08/21 0.45 0.59 0.40 0.45 27,900 0.45
2009/08/20 0.47 0.49 0.47 0.49 42,200 0.49
2009/08/19 0.50 0.50 0.49 0.49 55,100 0.49
2009/08/18 0.49 0.59 0.49 0.54 36,034 0.54
2009/08/17 0.50 0.54 0.47 0.47 27,497 0.47
2009/08/14 0.51 0.51 0.51 0.51 2,500 0.51
2009/08/13 0.51 0.51 0.51 0.51 17,505 0.51
2009/08/12 0.52 0.53 0.52 0.53 6,200 0.53
2009/08/11 0.52 0.52 0.52 0.52 32,350 0.52
2009/08/10 0.52 0.52 0.50 0.51 33,800 0.51
2009/08/07 0.51 0.52 0.51 0.51 22,700 0.51
2009/08/06 0.50 0.50 0.46 0.50 33,500 0.50
2009/08/05 0.46 0.52 0.46 0.50 58,290 0.50
2009/08/04 0.46 0.46 0.46 0.46 4,366 0.46
2009/08/03 0.47 0.50 0.46 0.47 42,400 0.47
2009/07/31 0.47 0.47 0.47 0.47 1,000 0.47
2009/07/30 0.43 0.44 0.43 0.44 5,100 0.44
2009/07/29 0.43 0.47 0.43 0.47 5,400 0.47
2009/07/28 0.47 0.47 0.47 0.47 - 0.47
2009/07/27 0.47 0.47 0.47 0.47 4,000 0.47
2009/07/24 0.47 0.47 0.47 0.47 - 0.47
2009/07/23 0.47 0.47 0.47 0.47 6,000 0.47
2009/07/22 0.44 0.47 0.44 0.45 29,500 0.45
2009/07/21 0.45 0.45 0.45 0.45 - 0.45
2009/07/20 0.45 0.45 0.45 0.45 - 0.45
2009/07/17 0.45 0.45 0.45 0.45 5,000 0.45
2009/07/16 0.49 0.49 0.45 0.45 43,137 0.45
2009/07/15 0.49 0.49 0.47 0.47 28,500 0.47
2009/07/14 0.43 0.43 0.43 0.43 500 0.43
2009/07/13 0.40 0.48 0.40 0.48 36,702 0.48
I believe that we should see a good pop, once the radars get going.
OISI News:
Ophthalmic Imaging Systems Receives FDA Clearance to Market Revolutionary New Portable Digital Imaging Device
SACRAMENTO, CA -- (Marketwire) -- 11/30/09 -- Ophthalmic Imaging Systems ("OIS" or "the Company") (OTCBB: OISI), a leading digital imaging and informatics company, today announced that its revolutionary new portable imaging device, the OIS EyeScan, has received 510(k) market clearance from the U.S. Food and Drug Administration (FDA).
The OIS EyeScan is the only portable imaging device that is capable of imaging both the anterior and posterior segment of the eye. Powered by OIS WinStation Software, and fully integrated with the OIS Symphony Image Management Solution, OIS EyeScan will deliver more functionality than has ever been available in an imaging device. With the ability to capture images from a customized chin rest, from a slit lamp adapter or as a handheld device, the OIS EyeScan is versatile enough to add value to any ophthalmologist's practice. The OIS EyeScan has been designed to be small enough to fit easily in the trunk of a car, and portable enough to be used at multiple locations in one day. For more information, an electronic brochure is available online at http://www.oisi.com/OISEyeScan.
"By receiving FDA 510(k) clearance for the OIS EyeScan, we can now actively market the device to our customers. The OIS EyeScan is already highly anticipated among our customers and we are looking forward to delivering this device to the market," stated Gil Allon, Chief Executive Officer of OIS. "The EyeScan brings an entirely new level of versatility to ophthalmologists' offices, and is unlike any other single diagnostic imaging device ever released."
About Ophthalmic Imaging Systems
Ophthalmic Imaging Systems (www.oisi.com) is the leading provider of ophthalmic digital imaging systems. The Company designs, develops, manufactures and markets digital imaging systems, image management and integrated EMR/Practice Management solutions for the eye care market. With over twenty years in the ophthalmic imaging business, the Company has consistently introduced new, innovative technologies. Through OIS' wholly-owned subsidiary, Abraxas Medical Solutions, the company provides Electronic Medical Records and Practice Management software to Ophthalmology as well as OB/GYN, Orthopedic and Primary care. The Company markets and supports its products through an extensive network of dealers, distributors, and direct representatives.
Statements in this press release which are not historical data are forward-looking statements which involve known and unknown risks, uncertainties, or other factors not under the Company's control, which may cause actual results, performance, or achievements of the Company to be materially different from the results, performance, or other expectations implied by these forward-looking statements. These factors include, but are not limited to, those detailed in the Company's periodic filings with the Securities and Exchange Commission.
CONTACTS:
Gil Allon
CEO
Ariel Shenhar
CFO
(916) 646-2020
INVESTOR RELATIONS
Todd Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
OPHTHALMIC IMAGING SYSTEMS
221 Lathrop Way, Suite I
Sacramento, CA 95815
Followers
|
3
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
56
|
Created
|
10/18/08
|
Type
|
Free
|
Moderators |
Updating soon.
http://twitter.com/mrgreenpenny
Email: mrgreenpenny@yahoo.com
OISI
Ophthalmic Imaging Systems
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |